<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta name="viewport" content="width=device-width, initial-scale=0.75">
<title>Family Medicine Algorithms</title>
<style>
  body {
    background-color: #f0f4f8;
    color: #111;
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    margin: 0;
    padding: 0;
  }
  header {
    background-color: #0077b6;
    padding: 30px 20px;
    text-align: center;
    border-bottom: 1px solid #ccc;
  }
  header h1 {
    color: white;
    margin: 0;
    font-size: 28px;
  }
  .container {
    padding: 30px 20px;
    max-width: 900px;
    margin: auto;
  }
  .accordion {
    background-color: #ffffff;
    color: #000;
    cursor: pointer;
    padding: 22px;
    width: 100%;
    text-align: center;
    border: none;
    outline: none;
    font-size: 17px;
    margin-bottom: 10px;
    border-radius: 8px;
    border: 1px solid #ccc;
  }
  .active {
    background-color: #e0e0e0;
  }
  .panel {
    display: none;
    background-color: #ffffff;
    color: #111;
    padding: 20px;
    font-size: 16px;
    line-height: 1.7;
    border-radius: 0 0 8px 8px;
    border-left: 1px solid #ccc;
    border-right: 1px solid #ccc;
    border-bottom: 1px solid #ccc;
  }
  .panel strong { color: #000; }
  .note {
    color: #555;
    font-style: italic;
  }
  .dark-mode {
    background-color: #111 !important;
    color: #f1f1f1 !important;
  }
  .dark-mode header {
    background-color: #000 !important;
    color: #d4af37 !important;
  }
  .dark-mode .accordion,
  .dark-mode .panel {
    background-color: #1e1e1e !important;
    color: #f1f1f1 !important;
    border: 1px solid #333 !important;
  }
  .dark-mode .accordion {
    text-align: center;
  }
  .dark-mode .panel strong {
    color: #fff !important;
  }
  .dark-mode .note {
    color: #ccc !important;
  }
  .theme-toggle {
    position: fixed;
    top: 20px;
    right: 20px;
    background: #0077b6;
    color: white;
    border: none;
    border-radius: 20px;
    padding: 10px 16px;
    cursor: pointer;
    font-size: 16px;
    z-index: 9999;
    box-shadow: 0 2px 6px rgba(0,0,0,0.2);
  }
</style>
</head>
<body>
<header>
  <h1>üìã Family Medicine Algorithms</h1>
</header>
<div class="container">

    <button class="accordion">1. Hypertension Management üíä</button>
    <div class="panel">
      <ol>
        <li><strong>1. Diagnosis:</strong><br/>
          ‚Ä¢ Confirm BP ‚â•140/90 mmHg on ‚â•2 occasions, at least 1 week apart.<br/>
          ‚Ä¢ Use ambulatory or home BP monitoring if white coat suspected.
        </li>
        <li><strong>2. Risk Stratification:</strong><br/>
          ‚Ä¢ Evaluate CV risk (lipids, diabetes, smoking).<br/>
          ‚Ä¢ Check for TOD: ECG, creatinine/eGFR, urinalysis, fundoscopy.
        </li>
        <li><strong>3. Lifestyle Modifications (for all):</strong><br/>
          ‚Ä¢ Reduce salt (<2.3g/day), DASH diet, physical activity (30 min/day), weight loss, smoking cessation.
        </li>
        <li><strong>4. Initiate Pharmacotherapy:</strong><br/>
          ‚Ä¢ Start if BP ‚â•160/100, or ‚â•140/90 + diabetes/CKD/CVD risk.<br/>
          ‚Ä¢ First-line options:<br/>
          &nbsp;&nbsp;‚Äì ACEi: Lisinopril 10‚Äì40 mg once daily<br/>
          &nbsp;&nbsp;‚Äì ARB: Losartan 50‚Äì100 mg once daily<br/>
          &nbsp;&nbsp;‚Äì CCB: Amlodipine 5‚Äì10 mg once daily<br/>
          &nbsp;&nbsp;‚Äì Thiazide: Hydrochlorothiazide 12.5‚Äì25 mg daily
        </li>
        <li><strong>5. Follow-Up:</strong><br/>
          ‚Ä¢ Recheck in 2‚Äì4 weeks. Titrate dose or add second agent.<br/>
          ‚Ä¢ Check labs (K‚Å∫, Cr) within 2‚Äì4 weeks if on ACEi/ARB or diuretic.
        </li>
        <li><strong>6. Treatment Targets:</strong><br/>
          ‚Ä¢ General: &lt;140/90 mmHg<br/>
          ‚Ä¢ High-risk (e.g. DM, CKD, CVD): &lt;130/80 mmHg if tolerated
        </li>
      </ol>
      <p class="note">üìö Sources: UpToDate, Saudi Hypertension Guidelines, JNC8</p>
    </div>
    

    <button class="accordion">2. DM Type (II) Management üç¨</button>
    <div class="panel">
      <ol>
        <li><strong>1. Diagnosis:</strong><br/>
          ‚Ä¢ FPG ‚â•126 mg/dL (7.0 mmol/L) OR<br/>
          ‚Ä¢ HbA1c ‚â•6.5% OR<br/>
          ‚Ä¢ 2-hr OGTT ‚â•200 mg/dL OR<br/>
          ‚Ä¢ Random glucose ‚â•200 mg/dL with symptoms
        </li>
        <li><strong>2. Initial Workup:</strong><br/>
          ‚Ä¢ HbA1c, lipid profile, renal function, urine ACR<br/>
          ‚Ä¢ BP, weight, foot exam, retinal exam (refer ophtho)
        </li>
        <li><strong>3. Lifestyle Interventions:</strong><br/>
          ‚Ä¢ Diet: calorie control, carb moderation<br/>
          ‚Ä¢ Exercise: ‚â•150 min/week aerobic activity<br/>
          ‚Ä¢ Weight loss goal: 5‚Äì10%
        </li>
        <li><strong>4. Start Pharmacologic Therapy:</strong><br/>
          ‚Ä¢ First-line: Metformin 500 mg once/twice daily, titrate to 2000 mg/day<br/>
          ‚Ä¢ Avoid if eGFR &lt;30. Hold during acute illness or contrast
        </li>
        <li><strong>5. Add Second Agent:</strong><br/>
          ‚Ä¢ ASCVD: Add GLP-1 RA or SGLT2i<br/>
          ‚Ä¢ CKD/HF: Prefer SGLT2i<br/>
          ‚Ä¢ Need weight loss: GLP-1 RA<br/>
          ‚Ä¢ Cost concern: SU or TZD
        </li>
        <li><strong>6. HbA1c Target:</strong><br/>
          ‚Ä¢ General target: &lt;7.0%<br/>
          ‚Ä¢ Individualize based on age, comorbidities, hypoglycemia risk
        </li>
        <li><strong>7. Monitoring:</strong><br/>
          ‚Ä¢ Check HbA1c every 3‚Äì6 months<br/>
          ‚Ä¢ Annual labs: lipids, renal, foot, retina
        </li>
      </ol>
      <p class="note">üìö Sources: UpToDate, ADA 2024, Saudi Diabetes Guidelines</p>
    </div>
    

    <button class="accordion">3. Dyslipidemia Management üß¨</button>
    <div class="panel">
      <ol>
        <li><strong>1. Screening:</strong><br/>
          ‚Ä¢ Adults ‚â•40 yrs OR ‚â•20 yrs with diabetes, smoking, hypertension, obesity.<br/>
          ‚Ä¢ Fasting lipid profile: Total, LDL, HDL, TG
        </li>
        <li><strong>2. Risk Assessment:</strong><br/>
          ‚Ä¢ Use ASCVD calculator or check risk category (low/moderate/high/very high)<br/>
          ‚Ä¢ DM, CKD, smoking, HTN increase risk
        </li>
        <li><strong>3. Lifestyle Modification (all patients):</strong><br/>
          ‚Ä¢ Diet: low saturated fat, more fiber<br/>
          ‚Ä¢ Exercise: ‚â•150 min/week<br/>
          ‚Ä¢ Weight loss, smoking cessation
        </li>
        <li><strong>4. Start Statin Therapy:</strong><br/>
          ‚Ä¢ Moderate risk: Atorvastatin 10‚Äì20 mg<br/>
          ‚Ä¢ High risk: Atorvastatin 40‚Äì80 mg or Rosuvastatin 20 mg
        </li>
        <li><strong>5. Targets:</strong><br/>
          ‚Ä¢ High-risk: LDL &lt; 2.6 mmol/L (<100 mg/dL)<br/>
          ‚Ä¢ Very high-risk (e.g. ASCVD, DM + RF): LDL &lt; 1.8 mmol/L (<70 mg/dL)
        </li>
        <li><strong>6. Monitoring:</strong><br/>
          ‚Ä¢ Repeat lipids in 6‚Äì12 weeks after starting statin<br/>
          ‚Ä¢ Check liver enzymes if symptomatic
        </li>
      </ol>
      <p class="note">üìö Sources: UpToDate, Saudi Lipid Guidelines, ACC/AHA 2019</p>
    </div>


    <button class="accordion">4. Upper Respiratory Tract Infection (URTI) ü§ß</button>
    <div class="panel">
      <ol>
        <li><strong>1. Common Causes:</strong><br/>
          ‚Ä¢ Viral: Rhinovirus, Influenza, Coronavirus<br/>
          ‚Ä¢ Bacterial (rare): Group A Streptococcus (pharyngitis)
        </li>
        <li><strong>2. Symptoms:</strong><br/>
          ‚Ä¢ Sore throat, nasal congestion, cough, fever, fatigue<br/>
          ‚Ä¢ Red flags: dyspnea, chest pain, high fever >3 days
        </li>
        <li><strong>3. Evaluation:</strong><br/>
          ‚Ä¢ Centor Score for pharyngitis<br/>
          ‚Ä¢ No labs/radiology needed unless concern for complications
        </li>
        <li><strong>4. Management:</strong><br/>
          ‚Ä¢ Supportive: Paracetamol, fluids, rest<br/>
          ‚Ä¢ Nasal saline, decongestants (short term), throat lozenges
        </li>
        <li><strong>5. Antibiotics:</strong><br/>
          ‚Ä¢ Not routinely indicated<br/>
          ‚Ä¢ Consider Penicillin V 500 mg BID x10 days if Centor ‚â•3 + positive swab
        </li>
        <li><strong>6. Patient Education:</strong><br/>
          ‚Ä¢ Explain viral nature and expected duration (5‚Äì10 days)<br/>
          ‚Ä¢ Return precautions if worsening
        </li>
      </ol>
      <p class="note">üìö Sources: UpToDate, NICE Guidelines, CDC</p>
    </div>


    <button class="accordion">5. Depression Screening & Management üòî</button>
    <div class="panel">
      <ol>
        <li><strong>1. Screening:</strong><br/>
          ‚Ä¢ Ask PHQ-2: "Little interest? Feeling down?"<br/>
          ‚Ä¢ If positive ‚Üí do full PHQ-9
        </li>
        <li><strong>2. Diagnosis:</strong><br/>
          ‚Ä¢ ‚â•5 symptoms for ‚â•2 weeks (incl. low mood or anhedonia)<br/>
          ‚Ä¢ Rule out hypothyroidism, substance use
        </li>
        <li><strong>3. Severity-Based Approach:</strong><br/>
          ‚Ä¢ Mild: Lifestyle + watchful waiting<br/>
          ‚Ä¢ Moderate: Start SSRI + counseling<br/>
          ‚Ä¢ Severe: SSRI + refer psychiatry ¬± urgent intervention
        </li>
        <li><strong>4. First-line Medications:</strong><br/>
          ‚Ä¢ Sertraline: start 25‚Äì50 mg daily, max 200 mg<br/>
          ‚Ä¢ Fluoxetine: start 10‚Äì20 mg daily, max 60 mg
        </li>
        <li><strong>5. Monitoring:</strong><br/>
          ‚Ä¢ Reassess in 2‚Äì4 weeks<br/>
          ‚Ä¢ Watch for suicidality, side effects
        </li>
        <li><strong>6. Duration:</strong><br/>
          ‚Ä¢ Continue for at least 6‚Äì9 months after improvement<br/>
          ‚Ä¢ Consider long-term if recurrent episodes
        </li>
      </ol>
      <p class="note">üìö Sources: NICE Guidelines, UpToDate, WHO mhGAP</p>
    </div>


    <button class="accordion">6. Low Back Pain Management üßç‚Äç‚ôÇÔ∏è</button>
    <div class="panel">
      <ol>
        <li><strong>1. Initial Assessment:</strong><br/>
          ‚Ä¢ History + physical exam<br/>
          ‚Ä¢ Identify red flags: trauma, weight loss, fever, cancer history, night pain, saddle anesthesia, weakness
        </li>
        <li><strong>2. No Red Flags:</strong><br/>
          ‚Ä¢ Diagnose as non-specific mechanical back pain<br/>
          ‚Ä¢ No imaging needed initially
        </li>
        <li><strong>3. First-Line Treatment:</strong><br/>
          ‚Ä¢ Paracetamol 500‚Äì1000 mg Q6H PRN<br/>
          ‚Ä¢ Ibuprofen 400 mg TID with meals (if no contraindications)<br/>
          ‚Ä¢ Gentle movement, activity encouragement
        </li>
        <li><strong>4. Consider Muscle Relaxants:</strong><br/>
          ‚Ä¢ E.g. Cyclobenzaprine 5‚Äì10 mg at bedtime (short-term)
        </li>
        <li><strong>5. Reassess in 2‚Äì4 Weeks:</strong><br/>
          ‚Ä¢ Most resolve in &lt;6 weeks<br/>
          ‚Ä¢ If persistent or red flags ‚Üí imaging (MRI preferred)
        </li>
        <li><strong>6. Patient Education:</strong><br/>
          ‚Ä¢ Avoid prolonged bed rest<br/>
          ‚Ä¢ Reassure: good prognosis in most cases
        </li>
      </ol>
      <p class="note">üìö Sources: UpToDate, NICE Guidelines, AAFP</p>
    </div>


    <button class="accordion">7. Chronic Asthma Management üå¨Ô∏è</button>
    <div class="panel">
      <ol>
        <li><strong>1. Diagnosis:</strong><br/>
          ‚Ä¢ Clinical: episodic wheeze, cough, dyspnea + response to bronchodilators<br/>
          ‚Ä¢ Confirm with spirometry if possible (FEV1 reversibility ‚â•12%)
        </li>
        <li><strong>2. Assess Control:</strong><br/>
          ‚Ä¢ Ask about symptoms, night awakenings, SABA use, activity limitation
        </li>
        <li><strong>3. Stepwise Therapy:</strong><br/>
          ‚Ä¢ Step 1: PRN low-dose ICS-formoterol<br/>
          ‚Ä¢ Step 2: Daily low-dose ICS (e.g. Budesonide 200‚Äì400 mcg/day)<br/>
          ‚Ä¢ Step 3: Low-dose ICS + LABA (e.g. Salmeterol)<br/>
          ‚Ä¢ Step 4: Medium-dose ICS + LABA<br/>
          ‚Ä¢ Step 5: Refer + consider biologics
        </li>
        <li><strong>4. Inhaler Technique & Adherence:</strong><br/>
          ‚Ä¢ Recheck at every visit<br/>
          ‚Ä¢ Use spacer if needed
        </li>
        <li><strong>5. Action Plan:</strong><br/>
          ‚Ä¢ Provide written asthma action plan (green/yellow/red zones)<br/>
          ‚Ä¢ Educate on when to increase meds or seek help
        </li>
        <li><strong>6. Follow-Up:</strong><br/>
          ‚Ä¢ Review control every 1‚Äì3 months<br/>
          ‚Ä¢ Consider stepping down if controlled ‚â•3 months
        </li>
      </ol>
      <p class="note">üìö Sources: GINA 2024, UpToDate, Saudi Asthma Guidelines</p>
    </div>


    <button class="accordion">8. Hypothyroidism Management ü¶ã</button>
    <div class="panel">
      <ol>
        <li><strong>1. Diagnosis:</strong><br/>
          ‚Ä¢ High TSH + Low Free T4 = Primary hypothyroidism<br/>
          ‚Ä¢ Common cause: Hashimoto‚Äôs thyroiditis (check anti-TPO antibodies)
        </li>
        <li><strong>2. Symptoms:</strong><br/>
          ‚Ä¢ Fatigue, weight gain, cold intolerance, constipation, dry skin, depression
        </li>
        <li><strong>3. Treatment:</strong><br/>
          ‚Ä¢ Levothyroxine 1.6 mcg/kg/day (full dose for young adults)<br/>
          ‚Ä¢ Start lower (25‚Äì50 mcg) in elderly or cardiac patients
        </li>
        <li><strong>4. Administration Tips:</strong><br/>
          ‚Ä¢ Take on empty stomach, same time daily<br/>
          ‚Ä¢ Avoid calcium/iron within 4 hours
        </li>
        <li><strong>5. Monitoring:</strong><br/>
          ‚Ä¢ Recheck TSH after 6‚Äì8 weeks of dose adjustment<br/>
          ‚Ä¢ Goal: Normalize TSH (typically 0.5‚Äì4.0 mIU/L)
        </li>
        <li><strong>6. Special Cases:</strong><br/>
          ‚Ä¢ Pregnancy: Increase dose by 30%, target TSH &lt;2.5<br/>
          ‚Ä¢ Subclinical (mild TSH elevation): Treat if symptoms, +TPO, or TSH >10
        </li>
      </ol>
      <p class="note">üìö Sources: UpToDate, ATA Guidelines, AMBOSS</p>
    </div>


    <button class="accordion">9. Obesity Management ‚öñÔ∏è</button>
    <div class="panel">
      <ol>
        <li><strong>1. Diagnosis:</strong><br/>
          ‚Ä¢ BMI ‚â•30 = Obesity<br/>
          ‚Ä¢ BMI 25‚Äì29.9 = Overweight<br/>
          ‚Ä¢ Measure waist circumference (‚Üë risk if >102 cm men, >88 cm women)
        </li>
        <li><strong>2. Risk Assessment:</strong><br/>
          ‚Ä¢ Screen for diabetes, hypertension, dyslipidemia, NAFLD, sleep apnea
        </li>
        <li><strong>3. Lifestyle Intervention (cornerstone):</strong><br/>
          ‚Ä¢ Diet: caloric deficit (‚Üì500‚Äì750 kcal/day)<br/>
          ‚Ä¢ Physical activity: ‚â•150 min/week<br/>
          ‚Ä¢ Behavioral support and follow-up
        </li>
        <li><strong>4. Pharmacologic Therapy:</strong><br/>
          ‚Ä¢ If BMI ‚â•30 OR ‚â•27 with comorbidities<br/>
          ‚Ä¢ Example: Orlistat 120 mg TID with meals (GI side effects)<br/>
          ‚Ä¢ Others (if available): Liraglutide, Semaglutide, Naltrexone/Bupropion
        </li>
        <li><strong>5. Bariatric Surgery:</strong><br/>
          ‚Ä¢ Consider if BMI ‚â•40 OR ‚â•35 with comorbidities and failed other methods
        </li>
        <li><strong>6. Monitoring:</strong><br/>
          ‚Ä¢ Monthly weight check initially<br/>
          ‚Ä¢ Target: ‚â•5% weight loss in 3‚Äì6 months
        </li>
      </ol>
      <p class="note">üìö Sources: UpToDate, Saudi Obesity Guidelines, AACE 2023</p>
    </div>


    <button class="accordion">10. Smoking Cessation üö≠</button>
    <div class="panel">
      <ol>
        <li><strong>1. Ask & Document:</strong><br/>
          ‚Ä¢ Ask every patient about tobacco use<br/>
          ‚Ä¢ Document smoking status in chart
        </li>
        <li><strong>2. Advise:</strong><br/>
          ‚Ä¢ Give clear, strong, personalized advice to quit
        </li>
        <li><strong>3. Assess Readiness:</strong><br/>
          ‚Ä¢ Use 5 stages of change (precontemplation ‚Üí maintenance)<br/>
          ‚Ä¢ If not ready: motivational interviewing
        </li>
        <li><strong>4. Assist (if ready):</strong><br/>
          ‚Ä¢ Set quit date within 2 weeks<br/>
          ‚Ä¢ Offer pharmacotherapy + behavioral support
        </li>
        <li><strong>5. First-line Medications:</strong><br/>
          ‚Ä¢ Nicotine patch 21 mg/day (‚Üì gradually)<br/>
          ‚Ä¢ Bupropion SR 150 mg daily √ó 3 days, then BID (start 1 week before quit)<br/>
          ‚Ä¢ Varenicline: 0.5 mg daily ‚Üí 1 mg BID (start 1 week before quit)
        </li>
        <li><strong>6. Follow-Up:</strong><br/>
          ‚Ä¢ Reassess in 1‚Äì2 weeks post quit date<br/>
          ‚Ä¢ Support relapse prevention
        </li>
      </ol>
      <p class="note">üìö Sources: UpToDate, WHO, CDC, Saudi Tobacco Control Guidelines</p>
    </div>

</div>
<script>
  var acc = document.getElementsByClassName("accordion");
  for (var i = 0; i < acc.length; i++) {
    acc[i].addEventListener("click", function() {
      this.classList.toggle("active");
      var panel = this.nextElementSibling;
      if (panel.style.display === "block") {
        panel.style.display = "none";
      } else {
        panel.style.display = "block";
      }
    });
  }
  function toggleTheme() {
    document.body.classList.toggle('dark-mode');
    localStorage.setItem('theme', document.body.classList.contains('dark-mode') ? 'dark' : 'light');
  }
  window.onload = function() {
    if (localStorage.getItem('theme') === 'dark') {
      document.body.classList.add('dark-mode');
    }
  }
</script>
<button class="theme-toggle" onclick="toggleTheme()">üåì</button>
</body>
</html>
